OVID

Ovid Therapeutics Inc. (OVID) - Q3 2024 10-Q Summary

Business Context and Reporting Period

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for brain conditions with significant unmet need. This report covers the quarterly period ended September 30, 2024. The company is classified as a smaller reporting company and an emerging growth company. As of the filing date, the company had 71,009,866 shares of common stock outstanding.

Key Financial Metrics

Material Changes and Unusual Items

• Royalty Monetization Liability Adjustment: The most significant financial event was a $29.0 million reduction in the royalty monetization liability related to the Ligand Pharmaceuticals agreement. This was recognized as "Other income" in the nine months ended September 30, 2024. The adjustment resulted from Takeda's Phase 3 topline results for soticlestat, which missed primary endpoints for Dravet and Lennox-Gastaut syndromes, leading management to lower the probability of commercialization to 7.5% and 0%, respectively.
• Fraudulent Transfer Loss: The company recognized a $1.8 million loss in Q3 2024 due to a business email compromise at a development partner, resulting in a fraudulent transfer of funds. This was recorded in "Other income (expense), net."
• Organizational Restructuring: In June 2024, the company reduced its workforce by 17 employees (approximately 43% of headcount) to extend its cash runway. This resulted in $3.7 million in severance costs recognized during the nine months ended September 30, 2024.
• Operating Expenses: Research and Development (R&D) expenses increased by $12.9 million year-over-year for the nine-month period, driven by the acceleration of preclinical and clinical development for candidates OV329, OV350, and OV888/GV101, as well as restructuring costs. General and Administrative (G&A) expenses decreased by $2.6 million due to the workforce reduction.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($62.7 million) are sufficient to fund operations for at least the next 12 months. The company expects to incur significant operating losses for the foreseeable future.
• Pipeline Updates:
  • OV329: Phase 1 study ongoing; topline data expected in 2025.
  • OV350: Regulatory application for Phase 1 trial expected before year-end 2024; first-in-human studies anticipated in Q1 2025.
  • OV888/GV101: Phase 2 proof-of-concept study in cerebral cavernous malformations (CCM) has been paused to evaluate clinical design learnings from competitor trials.
  • Soticlestat: Takeda is engaging with regulators regarding next steps following Phase 3 results. Future royalty and milestone payments remain uncertain.
• Internal Control Weaknesses: The company identified material weaknesses in internal control over financial reporting related to vendor payment information changes and susceptibility to spear phishing. This weakness directly led to the $1.8 million fraudulent transfer. A remediation plan is underway.
• Risks: Key risks include the failure to raise additional capital, the uncertainty of soticlestat commercialization, clinical trial failures, and the potential inability to recover the fraudulent funds.

Investor Verification Checklist

• Verify the status of the $1.8 million fraudulent transfer recovery efforts and any potential insurance claims.
• Monitor the progress of the remediation plan for the identified material weaknesses in internal controls over financial reporting.
• Assess the impact of the soticlestat Phase 3 results on the likelihood of future royalty and milestone payments from Takeda.
• Review the timeline for the OV350 Phase 1 trial and the strategic rationale for pausing the OV888/GV101 Phase 2 study.
• Track the company's cash burn rate relative to the $62.7 million cash balance to confirm the 12-month runway estimate.